Pulmonary sequestration associated with a synchronous elevation of carbohydrate antigen 50 and 19-9: a case report

Shaozi Fu, Haitao Wang

Department of Cardiothoracic Surgery, Zhejiang Provincial People's Hospital, Hangzhou 310000, China

Correspondence to: Haitao Wang, MD. Department of Cardiothoracic Surgery, Zhejiang Provincial People's Hospital, #158 Shangtang Road, Hangzhou 310000, China. Email: 443292584@qq.com.

Abstract: This report describes a 37-year-old woman who experienced elevated serum carbohydrate antigen 19-9 (CA19-9) and carbohydrate antigen 50 (CA50). Intralobar pulmonary sequestration was confirmed via enhanced chest computed tomography (CT) scanning and positron emission tomography/computed tomography (PET/CT), which indicated two abnormal vessels arising from the descending thoracic aorta. Lobectomy of the left inferior lobe was performed as the optimal surgical approach and the pathological analysis met the diagnosis of intralobar pulmonary sequestration. Review of the patient's serum levels of CA50 and CA19-9 showed that these two tumor markers significantly decreased after surgery and finally went down to normal values. Therefore, the synchronically significant elevation of serum CA50 and CA19-9 was due to intralobar pulmonary sequestration.

Keywords: Pulmonary sequestration; tumor marker

Submitted Mar 10, 2018. Accepted for publication May 10, 2018.
doi: 10.21037/atm.2018.05.18
View this article at: http://dx.doi.org/10.21037/atm.2018.05.18

Introduction

Carbohydrate antigen 19-9 (CA19-9) and carbohydrate antigen 50 (CA50) are widely considered as a gastrointestinal tumor marker. However, they can also elevate in some other diseases, such as chronic hepatitis, chronic pancreatitis, cholelithiasis, chronic glomerulonephritis, and myelodysplastic syndromes (1).

Pulmonary sequestration is a benign pulmonary disease. Previous researches show that pulmonary sequestration is associated with some tumor markers at times (2), mostly CA19-9 (3). In this case, we are the first to report a synchronically significant elevation of serum CA50 and CA19-9 in pulmonary sequestration.

Case presentation

A 37-year-old woman complained for a significant elevation of CA50 and CA19-9, which was found in an annual medical examination. Computed tomography (CT) scanning of the whole abdomen was performed and didn't show any positive findings. The patient did not manifest any symptoms, such as cough, hemoptysis and so on. The laboratory examinations revealed a significant elevation of CA50 and CA19-9, which highly reached to 50.02 and 729.48 U/mL respectively. The enhanced CT scanning of the chest (Figure 1A) and the CT angiography of the thoracic aorta (Figure 1B) showed two abnormal vessels arising from the descending thoracic aorta and consolidation of the posterior basal segment (S10) in the left inferior lobe. To exclude systemic malignant diseases, the positron emission tomography/computed tomography (PET/CT) was performed and didn't show any evidences of malignant signs. The maximum of standardized uptake value (SUVmax) of the consolidation of S10 segment was 4.8 (Figure 1C), which was prone to benign lesion. Collectively, pulmonary sequestration was considered as the primary diagnosis. Therefore, we performed a lobectomy of the left inferior lobe through a standard thoracotomy under general anesthesia with a single-lumen endotracheal tube for the patient. The pathological examination confirmed the diagnosis of intralobar pulmonary sequestration (Figure 1D).
Review of serum CA50 and CA19-9 levels showed that these two tumor markers decreased to 33.07 and 348.78 U/mL 5 days after surgery. As expected, they continuously decreased to 5.75 and 66.21 U/mL 1 month after surgery and returned to normal range 3 months after surgery (Table 1).

**Discussion**

CA50 and CA19-9, which are detected by monoclonal antibodies, are non-specific carbohydrate tumor markers. CA50 is commonly associated with gastrointestinal tumors, such as pancreatic cancer, colorectal cancer, gastric cancer and biliary tract cancer. Moreover, it has been reported that the elevation of CA50 could be found in other carcinomas besides of gastrointestinal tumors, such as non-small cell lung cancer, papillary thyroid carcinoma and myelodysplastic syndrome (4-6). CA19-9 mostly presents in gastrointestinal tumor, such as pancreatic cancer (7) and cholangiocarcinoma (8). Besides, some articles indicate that the elevation of CA19-9 can also be observed in benign diseases, such as uterine fibroids (9) and hydronephrosis (10).

As to pulmonary sequestration, it is a rare benign disease with symptoms of cough and expectoration. Sometimes,
the patient is asymptomatic with complaining for an elevation of tumor markers by screening of the medical examination. The accurate mechanism of the elevated serum tumor markers in pulmonary sequestration is still uncertain. However, some scholars have clarified that CA19-9 could be produced by bronchiolar epithelia after injury of the respiratory tract (11). The bronchial epithelial may synthesize and secrete CA19-9, which stores in the sequestrated lung and results in the elevated tumor markers in serum (12).

This case report indicated that the elevation of serum CA50 and CA19-9 may be correlated with pulmonary sequestration. In order to exclude malignant diseases, we performed PET/CT, which showed a negative result of malignant signs. The chest CT scanning showed two anomalous arteries, which gave a primary diagnosis of intralobar pulmonary sequestration. After a surgery of lobectomy, the serum CA50 and CA19-9 level decreased significantly. Three months after surgery, the serum CA50 and CA19-9 level went down to normal range. These results highly indicated the potential relationship between pulmonary sequestration and the abnormal rise of serum CA50 and CA19-9.

To the best knowledge of us, we are the first to report a synchronically significant elevation of serum CA50 and CA19-9 in pulmonary sequestration. Therefore, in case we find any unidentified elevation of the serum CA50 or CA19-9 in asymptomatic patients, excluding malignant diseases, pulmonary sequestration should be considered as a differential diagnosis in our opinions.

Acknowledgements

None.

Footnote

Conflict of Interest: The authors have no conflicts of interest to declare.

Informed Consent: Written informed consent was obtained from the patient for publication of this manuscript and any accompanying images.

References
